Morton Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.51M Buy
9,961
+399
+4% +$85.8K 0.34% 27
2026
Q1
$2.08M Buy
9,562
+133
+1% +$29.5K 0.31% 27
2025
Q4
$2.15M Sell
9,429
-66
-0.7% -$15K 0.33% 26
2025
Q3
$2.2M Sell
9,495
-227
-2% -$46.2K 0.36% 26
2025
Q2
$1.8M Buy
9,722
+275
+3% +$51.1K 0.32% 29
2025
Q1
$1.98M Buy
9,447
+92
+1% +$17.9K 0.38% 24
2024
Q4
$1.66M Buy
9,355
+168
+2% +$30.9K 0.31% 27
2024
Q3
$1.81M Buy
9,187
+358
+4% +$66.8K 0.36% 24
2024
Q2
$1.51M Sell
8,829
-556
-6% -$92.1K 0.36% 26
2024
Q1
$1.71M Sell
9,385
-263
-3% -$45.3K 0.46% 22
2023
Q4
$1.5M Buy
9,648
+186
+2% +$27.1K 0.44% 22
2023
Q3
$1.41M Buy
9,462
+64
+0.7% +$9.39K 0.5% 19
2023
Q2
$1.27M Buy
9,398
+34
+0.4% +$4.99K 0.43% 22
2023
Q1
$1.49M Sell
9,364
-563
-6% -$86.1K 0.53% 18
2022
Q4
$1.6M Buy
9,927
+5
+0.1% +$767 0.63% 16
2022
Q3
$1.33M Buy
9,922
+558
+6% +$80.1K 0.61% 16
2022
Q2
$1.43M Buy
9,364
+619
+7% +$94.6K 0.62% 16
2022
Q1
$1.42M Buy
8,745
+9
+0.1% +$1.31K 0.58% 16
2021
Q4
$1.18M Buy
+8,736
New +$1.03M 0.48% 22

Other funds holding ABBV

Morton Capital Management's ABBV Position: Q2 2026 in Review

Morton Capital Management increased its AbbVie (ABBV) stake by 4.2% in Q2 2026, buying an estimated $85.8K and bringing the position to 9,961 shares worth $2.51M. The position accounts for 0.34% of the portfolio, ranked #27.

Morton Capital Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 1,329 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Morton Capital Management held 9,961 shares of AbbVie worth $2.51M as of Q2 2026.
  • Morton Capital Management bought 399 AbbVie shares in Q2 2026, an estimated $85.8K.
  • AbbVie made up 0.34% of Morton Capital Management's portfolio in Q2 2026, its #27 holding.
  • Morton Capital Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 1,329 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Morton Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.